Compare Eli Lilly And Co (LLY) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Invesco NASDAQ 100 ETF — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Invesco NASDAQ 100 ETF trades at $309.41 (market cap $113.40B). The key difference: Eli Lilly And Co is far larger — about 9.2× Invesco NASDAQ 100 ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| LLY | QQQM | |
|---|---|---|
Market Cap | $1.04T | $113.40B |
Volume | 3,064,878 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $312.76 |
52-Week Low | $799.57 | $229.87 |
Typical Hold Time | 93 Days | 54 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
QQQM (Invesco NASDAQ 100 ETF) trades at $309.27, down 0.88% on the day, with a bullish technical signal from moving averages. The ETF tracks the NASDAQ-100 index with a low 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026. Technical indicators show support at $305 and resistance at $311, with neutral oscillator readings suggesting balanced momentum.
The outlook remains positive given the NASDAQ-100's growth exposure and cost efficiency versus QQQ. Risks include market concentration in technology stocks and potential volatility from macroeconomic factors. Institutional accumulation and favorable expense structure support long-term positioning, though investors should monitor index composition changes and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
